Our European practice assists clients in a broad range of regulatory, litigation, and corporate transactional matters to overcome the legal, public policy, and regulatory issues they face as they conduct business in the European environment. Our clients include multinational corporations and financial institutions, governments, international organizations, and others.They come to us from a broad array of industries, including fast moving consumer goods, pharmaceuticals and medical devices, media and communications, IT, financial services, consumer electronics, shipping and general manufacturing.

Based in London, Brussels, and Frankfurt, our European practice has a stellar reputation for regulatory advice within the life sciences, telecommunications and financial services sectors. In addition we provide the full spectrum of competition law/antitrust services: structuring and obtaining clearance for corporate transactions; advising on application of the law to agreements, conduct, and corporate strategies; tailor-made competition compliance training and auditing; and representation before EU and national competition authorities around the world, as well as in EU and national courts. Our experience with EU law also includes free movement of goods, technical standards, chemical regulation, and general consumer-protection issues.

Our attorneys support clients in complex and sometimes groundbreaking projects often involving multi-disciplinary team-working to achieve the end goal, including in the areas of intellectual property, white collar crime, litigation, arbitration and in life sciences- product liability litigation, competition law and corporate transactional areas. We count some of the world's largest global pharmaceutical and medical device companies among our clients, and our practice is recognized for its leadership in this arena. The firm's life sciences practice was described by Chambers UK as "a leading force for regulatory work in the life sciences sector."


European Competition enforcement in the pharmaceutical sector: more to be expected?
BioSlice Blog
Impact of UK's Temporary Tariff Regime on Life Sciences
BioSlice Blog
GDPR and clinical trials—more clarity?
BioSlice Blog
EU-US Privacy Shield: Safe for another year—but trouble lies ahead
The Digital Watcher
Implications of Recent EU and UK Court Decisions in the Pharmaceutical Sector
Arnold & Porter's Future Pharma Forum, London, England

Email Disclaimer